Topic summary

Ipamorelin selectivity claims and where they came from

Compounds › Secretagogues & GH axis GHRP class tesamorelin ipamorelin Closed

This is a generated summary. It shows the 8 most-liked posts from a topic of 57, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

t.ibarraTL2 Moderator7 Jan 2025#5

c.wijnberg, post #4: the opening post answers the question as asked. The question underneath it is different. Secretagogues and glucose tolerance: there is a mechanistic concern that sustained growth hormone elevation might impair glucose tolerance. The clinical relevance of this concern in practice is not well established. Go to post

I read post #3 twice before replying, because I had assumed the opposite.

What a well-designed human trial of a secretagogue would look like: randomised, placebo-controlled, adequate sample size, IGF-1 as primary outcome, muscle and strength as secondary outcomes, adequate follow-up duration. Very few secretagogue trials meet that description.

28 likes in reply to #4 19mo

f.novakTL2 Moderator26 Feb 2025#16

r.bakken, post #3: Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is precisely why documentation quality matters more. A supplier page that clearly identifies the compound and the purity is more valuable for secretagogues than for incretin agonists where the evidence base is stronger. Go to post

Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is precisely why documentation quality matters more. A supplier page that clearly identifies the compound and the purity is more valuable for secretagogues than for incretin agonists where the evidence base is stronger.

27 likes in reply to #3 17mo

c.inglethorpeTL3Regular21 Mar 2025#22

CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin covalently and persists for days. The version without it does not persist. Supplier labelling frequently does not distinguish them clearly, so confirming which you have is important.

23 likes 16mo

BGiordanoTL2Member5 Apr 2025#26

KTurkington, post #13: IGF-1 as a surrogate: it is a better integrated measure than a spot growth hormone level and it is still a surrogate, with all the caveats that come with surrogates. Stable or rising IGF-1 is not the same as "this is working" in any health-related sense. Go to post

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

31 likes in reply to #13 16mo

lyophil_marginTL3Regular3 May 2025#34

s.bergstrom, post #14: Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

33 likes in reply to #14 15mo

j.habermannTL3Regular16 May 2025 · edited#38

a.cardoso, post #20: Coming back to post #18, because the follow-up matters more than the original answer. GHRH analogues versus ghrelin mimetics are often conflated but they are different mechanisms. GHRH analogues (like CJC-1295) cause the pituitary to release growth hormone. Ghrelin mimetics (like GHRPs) act on the ghrelin receptor directly. The effect… Go to post

Ipamorelin selectivity claims originate in preclinical characterisation and are reasonably well supported for what they claim: less effect on cortisol and prolactin than earlier GHRPs. Whether that translates to something clinically meaningful is a different question from whether the selectivity is real.

24 likes in reply to #20 14mo

r.danquahTL2 Moderator30 May 2025 · edited#42

post #41 is right about the mechanism and I think understates the practical bit.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

26 likes 14mo

r.chukwuTL2 Moderator12 Jul 2025#56

l.aguirre, post #46: post #45 answers the question as asked. The question underneath it is different. Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin… Go to post

Coming back to post #54, because the follow-up matters more than the original answer.

IGF-1 as a surrogate: it is a better integrated measure than a spot growth hormone level and it is still a surrogate, with all the caveats that come with surrogates. Stable or rising IGF-1 is not the same as "this is working" in any health-related sense.

28 likes in reply to #46 13mo

Read the full topic (57 posts)

This topic was referenced in

Tesamorelin has an approved indication — what that changes about the evidenceCompounds › Secretagogues & GH axis · 27 replies
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussionCompounds › Secretagogues & GH axis · 13 replies

Promoted into the documentation commons. The content of this topic is maintained at Tesamorelin — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

This topic was closed 90 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of…	+47	53	6.9k	2h
Why pulsatile secretion matters for interpreting secretagogue claims Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Why pulsatile secretion matters for interpreting secretagogue claims — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited…	+5	9	1.6k	15h
[2026 update] Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Closed Posting this under the heading it deserves: Evidence quality in the secretagogue literature: an honest assessment Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…	+14	18	3.1k	6mo
Reading a rodent study on a secretagogue without over-extrapolating Compounds › Secretagogues & GH axis observational data GHRP class CJC-1295 needs a source Closed Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of…	+50	54	32k	10mo
Tesamorelin has an approved indication — what that changes about the evidence Compounds › Secretagogues & GH axis observational data tesamorelin GHRP class CJC-1295 Tesamorelin has an approved indication — what that changes about the evidence — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-1 ( N Engl J…	+23	27	3.4k	1d

Related topics — sharing the tags GHRP class, tesamorelin, ipamorelin

Topic	Participants	Replies	Views	Activity
About the Secretagogues & GH axis category Compounds › Secretagogues & GH axis GHRP class CJC-1295 ipamorelin Pinned Wiki Closed Growth-hormone secretagogues and related compounds. Evidence quality here is markedly lower and we say so. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+6	10	1.1k	14mo
Why pulsatile secretion matters for interpreting secretagogue claims Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Why pulsatile secretion matters for interpreting secretagogue claims — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited…	+5	9	1.6k	15h
IGF-1 as a surrogate endpoint and its limitations — the long version Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved Closed On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do…	+14	18	53k	12mo
Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis ipamorelin observational data GHRP class tesamorelin Solved Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP…		2	25k	9d
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset Compounds › Secretagogues & GH axis GHRP class ipamorelin tesamorelin Under review The question in the title: Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N…	+60	64	25k	15mo